Protein Binding Basics for Lipitor
Lipitor (atorvastatin) is highly bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein, with binding exceeding 98% across therapeutic concentrations.[1] This means most of the drug circulates bound to proteins rather than free in plasma.
How Protein Binding Affects Bioavailability
Bioavailability measures the fraction of an oral dose that reaches systemic circulation unchanged. For Lipitor, absolute bioavailability is low at about 14%, mainly due to extensive first-pass metabolism in the gut and liver via CYP3A4, not protein binding.[1][2] Protein binding occurs post-absorption, primarily in plasma, so it does not directly reduce the amount entering circulation.
Bound drug is pharmacologically inactive and unavailable for tissue distribution or metabolism until dissociated. High binding limits free drug fraction (typically <2% for Lipitor), slowing distribution but not altering total bioavailability.[3]
Displacement Interactions and Bioavailability Risks
Protein binding indirectly influences bioavailability if displaced by other drugs. Competitors for albumin sites—like fibrates, cyclosporine, or erythromycin—can increase free atorvastatin, raising exposure without changing total plasma levels.[1][4] This elevates bioavailability-like effects (AUC increases up to 2-3 fold), heightening myopathy risk, but total drug absorption remains unchanged.[2]
No major food or disease states significantly alter Lipitor's protein binding or bioavailability.[1]
Comparison to Other Statins
Unlike pravastatin (low 50% binding), Lipitor's high binding reduces volume of distribution (381 L) versus simvastatin (similar low bioavailability but less binding).[3][5] Rosuvastatin (88% bound) shows higher bioavailability (20%) due to less first-pass effect.[5]
| Statin | Protein Binding | Oral Bioavailability | Main Limitation |
|--------|-----------------|----------------------|-----------------|
| Atorvastatin (Lipitor) | >98% | 14% | First-pass CYP3A4 |
| Simvastatin | 95% | 5% | First-pass CYP3A4 |
| Pravastatin | 50% | 18% | Poor absorption |
| Rosuvastatin | 88% | 20% | Active transport |
Clinical Implications for Patients
High binding stabilizes Lipitor during storage but requires dose adjustments in renal/hepatic impairment, where free fraction may rise slightly.[1] Genetic CYP3A4 variations affect bioavailability more than binding.[2]
[1]: Lipitor Prescribing Information (Pfizer)
[2]: DrugBank: Atorvastatin
[3]: Clinical Pharmacology Review, FDA NDA 20-702
[4]: Drug Interactions with Statins (AHA)
[5]: Statins Pharmacokinetics Comparison (PubMed)